Latest Insider Transactions at Marinus Pharmaceuticals, Inc. (MRNS)
This section provides a real-time view of insider transactions for Marinus Pharmaceuticals, Inc. (MRNS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MARINUS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MARINUS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2023
|
Charles Austin |
SELL
Open market or private sale
|
Direct |
1,073
-16.9%
|
$6,438
$6.49 P/Share
|
|
Feb 06
2023
|
Elan Ezickson |
SELL
Open market or private sale
|
Direct |
750
-11.81%
|
$4,500
$6.56 P/Share
|
|
Feb 06
2023
|
Seth H. Z. Fischer |
SELL
Open market or private sale
|
Direct |
1,018
-14.45%
|
$6,108
$6.54 P/Share
|
|
Jan 26
2023
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+32.36%
|
-
|
|
Jan 26
2023
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,648
+33.67%
|
-
|
|
Jan 26
2023
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,375
+28.77%
|
-
|
|
Jan 26
2023
|
Steven Pfanstiel CFO AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
28,130
+35.05%
|
-
|
|
Jan 26
2023
|
Seth H. Z. Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+33.82%
|
-
|
|
Jan 26
2023
|
Elan Ezickson |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+36.18%
|
-
|
|
Jan 26
2023
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
16,548
+31.98%
|
-
|
|
Jan 26
2023
|
Sara Nochur |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+36.18%
|
-
|
|
Jan 26
2023
|
Timothy M Mayleben |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+17.08%
|
-
|
|
Jan 26
2023
|
Christine Berni Silverstein |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+50.0%
|
-
|
|
Jan 26
2023
|
Charles Austin |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+36.18%
|
-
|
|
Nov 09
2022
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-5.54%
|
$6,020
$4.7 P/Share
|
|
May 24
2022
|
Steven Pfanstiel CFO AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
7,448
+23.69%
|
-
|
|
May 24
2022
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
19,305
+18.13%
|
-
|
|
May 24
2022
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
7,718
+23.69%
|
-
|
|
May 24
2022
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
5,790
+23.68%
|
-
|
|
Feb 04
2022
|
Santiago Arroyo Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Feb 04
2022
|
Charles Austin |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Feb 04
2022
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+38.72%
|
-
|
|
Feb 04
2022
|
Michael R Dougherty Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+45.36%
|
-
|
|
Feb 04
2022
|
Elan Ezickson |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Feb 04
2022
|
Seth H. Z. Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+44.4%
|
-
|
|
Feb 04
2022
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,150
+50.0%
|
-
|
|
Feb 04
2022
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
12,867
+50.0%
|
-
|
|
Feb 04
2022
|
Timothy M Mayleben |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+16.54%
|
-
|
|
Feb 04
2022
|
Sara Nochur |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Feb 04
2022
|
Steven Pfanstiel CFO AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,550
+50.0%
|
-
|
|
Feb 04
2022
|
Nicole Vitullo Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+29.92%
|
-
|
|
Mar 16
2021
|
Nicole Vitullo Director |
BUY
Other acquisition or disposition
|
Direct |
2,717
+42.39%
|
-
|
|
Mar 16
2021
|
Nicole Vitullo Director |
SELL
Other acquisition or disposition
|
Indirect |
17,804
-100.0%
|
-
|
|
Mar 15
2021
|
Nicole Vitullo Director |
SELL
Open market or private sale
|
Indirect |
4,250
-100.0%
|
$63,750
$15.87 P/Share
|
|
Mar 12
2021
|
Nicole Vitullo Director |
BUY
Other acquisition or disposition
|
Indirect |
6,192
+50.0%
|
-
|
|
Mar 12
2021
|
Nicole Vitullo Director |
SELL
Other acquisition or disposition
|
Indirect |
619,221
-100.0%
|
-
|
|
Mar 09
2021
|
Edward F Smith Former VP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
40,356
-75.23%
|
$686,052
$17.8 P/Share
|
|
Mar 09
2021
|
Edward F Smith Former VP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,927
+40.11%
|
$143,708
$4.16 P/Share
|
|
Dec 19
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
150,000
-1.83%
|
$1,050,000
$7.37 P/Share
|
|
Dec 18
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
300,000
-6.78%
|
$2,100,000
$7.5 P/Share
|
|
Dec 15
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
822,547
-7.99%
|
$6,580,376
$8.33 P/Share
|